Type 2 Diabetes Mellitus Clinical Trial
— POWEROfficial title:
Physical Activity for Overweight Youth at Risk for Type 2 Diabetes Mellitus (POWER) Trial
Background:
The investigators know that exercise helps children develop strong bones and muscles and
generally stay healthy. What is unclear however, is how much exercise a child needs to lower
their risk of developing type 2 diabetes.
Objective:
The investigators will try to find out whether high-intensity exercise for a short-period of
time is better than moderately intense exercise for improving the diabetes risk profile in
teens who are at risk for type 2 diabetes.
The working hypothesis is that exercise-mediated improvements in insulin sensitivity (a risk
factor for diabetes) will be greater following vigorous intermittent physical activity than
following low intensity physical activity in overweight adolescents 13-18 yrs at risk for
T2DM.
Brief Description of Research Project: Teenagers between the ages of 13 and 18 yrs, who are
at risk for type 2 diabetes (either by their family history or an abnormal response to
sugar) will be randomly assigned to one of two activity groups or a control group. The
activity groups will have supervised exercise sessions 3 to 5 days per week for 6 months.
One group will do high-intensity exercise, and the other will do lower-intensity exercise.
We will measure how sensitive their body is to insulin and the amount of fat in their muscle
and liver tissue at the beginning and end of the exercise intervention.
Status | Completed |
Enrollment | 120 |
Est. completion date | January 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 13 Years to 19 Years |
Eligibility |
Inclusion criteria: - Ethnic minority considered at risk for T2DM - In utero exposure to hyperglycemia (i.e. mother with gestational or frank diabetes during pregnancy) and/or evidence of hepatic steatosis (serum ALT > 60U/L, ultrasound or MRI-based evidence of steatosis). Exclusion criteria: - The investigators will exclude any patients that may have altered insulin sensitivity or tissue lipid content that would confound (mask) the effects of the intervention. - These include overweight adolescents who: - are diagnosed with impaired glucose tolerance or type 2 diabetes - are currently being treated with corticosteroids or atypical antipsychotics, as these agents significantly influence carbohydrate metabolism - are undergoing puberty (Tanner Stage 2-4) at the time of the investigation, as it is associated with transient changes in insulin sensitivity - have an orthopaedic injury that would prevent them from performing the intervention - have experienced weight loss or enrolled in weight loss program in the six months prior to the study - have a history of alcoholism or drug abuse. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Canada | Manitoba Institute of Child Health | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba | Manitoba Institute of Child Health |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insulin sensitivity measured from Bergman's frequently sampled intravenous glucose tolerance test | 6 months | No | |
Secondary | 1H-Magnetic resonance spectroscopy-derived measure of lipid content in liver and muscle tissue | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|